NCT05550766

Brief Summary

Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA damage response in the cell. Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders. the investigator hopes to assess prognosis of SCC \& BCC by using RXR-α biomarker \& attempts to use it in the treatment.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2022

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 20, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 22, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

September 22, 2022

Status Verified

September 1, 2022

Enrollment Period

9 months

First QC Date

September 20, 2022

Last Update Submit

September 20, 2022

Conditions

Non-melanoma Skin Cancer

Outcome Measures

Primary Outcomes (1)

  • Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma

    immuohistochemical expression of RXR-α in Squamous and Basal Cell Carcinoma

    One or two days after staining sections with the marker.

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Blocks obtained from cutaneous basal and squamous cell carcinoma tissue from 50 patients.

You may qualify if:

  • Squamous cell carcinoma and basal cell carcinoma.
  • Incisional \& excisional biopsies.
  • All the studied cases include sufficient materials for the immunohistochemical study 4. Complete clinical data

You may not qualify if:

  • Patients with a history of preoperative chemotherapy and/or radiotherapy.
  • Insufficient or tiny tissue biopsies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Fatma M.Hamdan

CONTACT

01000419587fatma.mohammad@med.sohag.edu.eg

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
demonstrator at pathology department

Study Record Dates

First Submitted

September 20, 2022

First Posted

September 22, 2022

Study Start

December 1, 2022

Primary Completion

September 1, 2023

Study Completion

December 1, 2023

Last Updated

September 22, 2022

Record last verified: 2022-09